Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

BACKGROUND: To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we investigated whether a single dose of a monoaminergic drug (methylphenidate) impro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Leijenaar, Jolien F., Groeneveld, Geert Jan, Klaassen, Erica S., Leeuwis, Anna E., Scheltens, Philip, Weinstein, Henry C., van Gerven, Joop M. A., Barkhof, Frederik, van der Flier, Wiesje M., Prins, Niels D.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947990/
https://ncbi.nlm.nih.gov/pubmed/31910895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0567-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars